News

News
Share this article
26 October 2020

The European Lead Factory launches online seminar series

COVID-19 has led to in-person events being suspended or cancelled. In an effort to keep the European Lead Factory (ELF) community connected and informed of ongoing activities, we are pleased to announce that we will be organising a series of webinars on different programmes and topics within the ELF portfolio.

News
Share this article
09 October 2020

The European Lead Factory supports Mental Health Awareness Day

Saturday, 10 October is World Mental Health Awareness Day. As a project involved in advancing drug candidates to address mental health disorders and other diseases, the European Lead Factory (ELF) supports World Mental Health Awareness Day. At the ELF, there are several initiatives running that could ultimately contribute to better treatments of mental health conditions.

News
Share this article
24 August 2020

Hit discovery in the European Lead Factory: output and experiences of assay development and high throughput screening

In a paper recently published in the SLAS Discovery Journal of Biomolecular Screening, European Lead Factory (ELF) scientists from the Pivot Park Screening Centre (PPSC), shared their experiences working on the assay development and ultra-High Throughput Screening (u-HTS) of crowed-sourced drug targets during the first phase of ELF (2013-2018).

News
Share this article
20 August 2020

Weekly online Q&A hour

Do you want to know more about the European Lead Factory (ELF), or do you need some guidance on submitting your screening proposal to ELF? With the next proposal submission deadline fast approaching on 4 September, you don’t want to miss out on this opportunity to get some first-hand support.

News
Share this article
22 July 2020

The European Lead Factory selects first COVID-19 proposal

Over the last few months, as the world has grappled with the COVID-19 pandemic, the European Lead Factory has been looking for ways to contribute collective efforts and assets to help deal with the crisis. As part of this focus, we have decided to prioritise COVID-19 related proposals through a fast-track procedure. We're proud to announce that the first proposal to tackle the SARS-CoV-2 infection has now been selected. The screening program aims to identify small-molecule inhibitors of viral entry into host cells.

News
Share this article
22 July 2020

ELF project member spotlight: Sabine Mulders, PPSC

One of the objectives of the European Lead Factory (ELF) is to provide guidance to the drug discovery community on successful strategies in lead discovery techniques. Helping to achieve this objective is the Pivot Park Screening Centre (PPSC), the ELF partner responsible for assay development and high-throughput screening. To find out more about what’s involved in the assay development process and the interactions with researchers, we spoke to Sabine Mulders, Chief Project Officer at PPSC.

News
Share this article
16 June 2020

Cancer metabolism research bolstered by ELF collaboration

Metabomed, an Israeli biotech company that has been successful in progressing results through the European Lead Factory (ELF), has discovered a series of potent and selective inhibitors of ACSS2 (the AcetylCoA Short chain Synthase 2 enzyme) for the treatment of cancers dependent on acetate metabolism.

News
Share this article
10 June 2020

The power of innovative partnerships in driving drug discovery

Two scientists well-known within the European Lead Factory community, Peter Simpson and Graeme Wilkinson, recently published a paper discussing the features underpinning a successful drug discovery consortium.

News
Share this article
22 May 2020

In Memoriam: Professor dr. Huib Ovaa

Professor dr. Huib Ovaa, ELF Academic Chemistry Partner and Public Programme Owner passed away on the 19th of May 2020.

News
Share this article
15 May 2020

Study conducted in collaboration with ELF discovers brain compound can blur traumatic memories

An international team of researchers led by Leiden chemist Mario van der Stelt, have found that a naturally occurring compound in the brain, anandamide, contributes to the reduction of traumatic memories.

Pages